Historical Press Releases

2014

Soligenix Announces Combination Vaccine for Ricin and Anthrax Achieves Simultaneous Protection

Princeton, NJ – July 9, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory...

Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS

Princeton, NJ – August 1, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix Advances Development of a Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax™

Princeton, NJ – August 7, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix Reports Second Quarter 2014 Financial Results, and Highlights Recent Accomplishments

Princeton, NJ – August 11, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine

Princeton, NJ – September 2, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Show per page